SLC7A11 and neoplasm: The underlying mechanism involves the downregulation of SLC3A2 and SLC7A11, the two subunits system XC–, by interferon-gamma released from immunotherapy-activated CD8+ T cells, thus reducing intracellular cysteine synthesis, decreasing antioxidant capacity and promoting lipid peroxidation and ferroptosis in tumour cells (Wang et al., 2019).